Genopsy, a cancer diagnosis startup, raised US$8.6 million from New Flight and institutional investors in a Series A round. Genopsy is the first spin-off from National Cancer Center.
Its proprietary liquid biopsy test “Nanowire” can detect cfDNA (cell-free DNA) 3 times more effectively than other tests in the market. Genopsy tested Nanowire with 900 cancer patients and the result showed superior sensitivity and accuracy over various types of cancers such as lung, bladder, breast and colon cancer.
Genopsy CEO Cho Young-Nam says that the proceeds will be used to develop a cancer diagnosis solution integrating proprietary liquid biopsy technology into digital healthcare.